Biosimilars Training Program 2022- Biosimilars: What Patients Should Know

(25:)

Biosimilars Training Program 2022- Improving Biosimilar Pharmacovigilance

(20:1econd)

Biosimilars Training Program 2022- Putting Your Biosimilars Training into Action

(20:)

Biosimilars Training Program 2022- Patient Advocate Perspective: Australia

(29:16)

Biosimilars Training Program 2022- Ensuring Biosimilar Policies Work for Patients

(24:11)

Biosimilars Training Program 2022- Physician Perspectives on Biosimilars

(24:42)

Biosimilars Training Program 2022- Introduction: Biologic and Biosimilar Medicines

(13:49)

Biosimilars Training Program 2022- Biosimilar Substitution Systems Around the World

(13:58)

Biosimilars Training Program 2022- Lessons from Patient Advocacy Experts

(29:49)

Biosimilars Training Program 2022- Patient Advocate Perspective: US

(29:44)

Biosimilars Training Program 2022 Patient Advocate Perspective Canada

(17:47)

Biosimilars Training Program 2022- Using the Patient Advocacy Toolkit

(9:31)

Biosimilars Training Program 2022- Day 2: Opening Remarks and Welcome

(8:46)

Biosimilars Training Program 2022- Day 2: Closing Remarks \u0026 Biosimilars Training Certificate

(3:17)

Biosimilars Training Program 2022- Non-Medical Switching- Physician Perspectives

(4:52)

Biosimilars Training Program 2022- Day 1: Opening Remarks and Welcome

(25:)

Biosimilars Training Program 2022- Day 1: Closing Remarks

(2:43)

Biosimilars: What you need to know

(28:36)

Training Programme on Biopharmaceutical Product Development

(2:32:23)